药石科技 reported revenue of ¥1.06B for the period ended 2026-06-30, +15.2% year on year. Net income was ¥0.10B, a 9.4% net margin on a 32.5% gross margin. The largest revenue line is 药物开发及商业化阶段的产品和服务 at 84% of the total. Free cash flow for the period was ¥0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.06B | +15.2% |
| Gross profit | ¥0.34B | — |
| Operating income | ¥0.12B | — |
| Net income | ¥0.10B | +37.2% |
| Gross margin | 32.5% | Net margin 9.4% |
| Revenue Q/Q | +8.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药物开发及商业化阶段的产品和服务 | ¥0.89B | 84.5% |
| 药物研究阶段的产品和服务 | ¥0.16B | 14.9% |
| 其他(补充) | ¥0.01B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.72B | 67.5% |
| R&D | ¥0.06B | 5.7% |
| SG&A | ¥0.14B | 13.4% |
| Tax & other | ¥0.02B | 1.7% |
| Item | Amount |
|---|---|
| Total assets | ¥5.38B |
| Total liabilities | ¥0.82B |
| Shareholders' equity | ¥4.57B |
| Equity / assets | 84.8% |
| Operating cash flow | ¥0.14B |
| Capital expenditure | ¥0.09B |
| Free cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | 193% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
宏达电子 ・ 润禾材料 ・ 乐歌股份 ・ 科创信息 ・ 科创新源 ・ 设研院 ・ 西菱动力 ・ 光弘科技 ・ 百邦科技 ・ 科顺股份 ・ 奥飞数据 ・ 明阳电路
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies